Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161447 | 0.89 | TP53 (0.43) | MAPTPTPN1LMNAHPGDMAOB | |
| SCHEMBL10161338 | 0.80 | HPGD (0.46) | MAPTTDP1PTPN1LMNAHPGD | |
| SCHEMBL10161340 | 0.79 | THRA (0.42) | MAPTTDP1PTPN1LMNAHPGD | |
| SCHEMBL10161454 | 0.79 | MAPT (0.39) | MAPTTDP1MAOBPOLB | |
| SCHEMBL10161339 | 0.78 | MRGPRX4 (0.46) | MAPTTDP1PTPN1LMNAHPGD | |
| SCHEMBL10161449 | 0.77 | MAPT (0.54) | MAPTTDP1LMNAHPGD | |
| SCHEMBL10196586 | 0.75 | ATM (0.42) | MAPTLMNA | |
| SCHEMBL977063 | 0.74 | MCL1 (0.47) | MAPTLMNAHPGDMAOBNR4A2 | |
| SCHEMBL6125199 | 0.74 | PTPN1 (0.47) | PTPN1LMNAHPGDMAOBMRGPRX4 | |
| SCHEMBL10161372 | 0.74 | BRD4 (0.40) | MAPTTDP1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | MAPT 734/4885TDP1 2230/4885PTPN1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.